Introduction
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The success of the in-vitro fertilization (IVF) and embryo Embryos produced by in-vitro fertilization (IVF) may transfer procedure is limited by the low proportion of embryos produce less platelet-activating factor (PAF) than is which undergo implantation. Factors which govern embryo optimal for development. It was previously shown that viability are poorly understood. One theory proposes that supplementation of culture media with PAF results in a embryos require autocrine growth factors for normal developsignificant increase in pregnancy rate. Human embryos ment (Paria and Dey, 1990) and that their production is are often cultured in media supplemented with serum disrupted by IVF procedures (O'Neill, 1997) . Plateletcontaining the enzyme PAF:acetylhydrolase (PAF:AH; EC activating factor (PAF) may be one of several possible 3.1.1.47), which hydrolyses PAF to its inactive form, lysoembryonic autocrine growth factors. In mice, embryos PAF. Thus, effective supplementation of media with PAF resulting from IVF release seven times less PAF than is requires inactivation of this enzyme. In this study we released by equivalent embryos fertilized in the reproductive examine the efficacy of the methods of PAF:AH deactivation tract (O'Neill, 1997), while human IVF embryos release low used for PAF supplementation of IVF culture medium.
but highly variable amounts of PAF (O'Neill et al., 1987 ; When the effectiveness of a commonly used acid treatment Vereecken et al., 1990) . Culture of embryos in vitro may protocol (pH 3.0 at room temperature for 5 min) was also compromise PAF production (Ryan et al., 1989) , while examined, it was found that it was not completely effective addition of PAF to culture media stimulates embryo metabolism for the majority of sera. When synthetic PAF was added (Ryan et al., 1990a) and development (O'Neill et al., 1989 , to 18 serum samples which had been acid treated, five had 1997; Roberts et al., 1993) , and results in significantly higher 90-100% of the original PAF remaining after 24 h (showing pregnancy rates following transfer (mouse: Ryan et al., 1990b ; that the acid treatment was effective), eight had from 10-human: O'Neill et al., 1989) . 90% of the original PAF remaining after 24 h, and five PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine) is samples had 0-10%. The extent to which PAF:AH was an ether phospholipid with an acetate group at its C2 glycerol susceptible to deactivation was not associated with the carbon. Upon removal of this acetate, PAF is converted to its activity in the serum prior to treatment, the serum inactive form, lyso-PAF (Blank et al., 1981) . An enzyme oestradiol concentration, or the cause of infertility. The known as PAF:acetylhydrolase (PAF:AH; EC 3.1.1.47) (Farr period of acidification and the incubation temperature were et al., 1980) catalyses this reaction, and appears to be essentially assessed to develop a new acid-treatment protocol (20 min ubiquitous in body fluids and cells. The presence of this acid treatment at 37°C) which was able to deactivate enzyme ensures that PAF is very rapidly degraded and can PAF:AH effectively in all sera (53/53) examined. A trial thus have only local short-term actions. This lability limits the was performed to assess the effect of acid treatment of potential for the addition of PAF to culture media when serum for 5 min at room temperature compared with the complex protein sources such as serum are present. Serum is new protocol (20 min at 37°C) on IVF outcome, following a rich source of PAF:AH; however, it has been shown that it PAF supplementation of IVF culture medium. Oocyte may be inactivated at low pH (Farr et al., 1980) . In a previous recovery, fertilization and embryo development rates were trial (O'Neill et al., 1989) we tested the effects on the outcome equivalent for both groups and approximately equal of human IVF of supplementing media with PAF following numbers of embryos were transferred or cryopreserved.
treatment of serum with acidification/neutralization to reduce Pregnancy rates were not significantly different (14.6 versus PAF:AH activity. In the current study we investigated the 20.0%) for the two treatments, with a trend towards efficacy of the method for PAF:AH deactivation. Extraction and bioassay of synthetic PAF Lakes, NJ, USA), the tube was immediately placed on ice during clot formation. After 1 h, the blood was centrifuged (2500 g for PAF was extracted by a modified version (Ammit and O'Neill, 1991 ) 10 min at 4°C) and the supernatant transferred to another 10 ml of the Bligh-Dyer organic extraction method (Bligh and Dyer, 1959) , tissue culture tube. The tube was incubated at 37°C until a fibrin clot followed by partial purification by thin-layer chromatography (Collier was fully formed (~1 h). After removing the fibrin clot, the resulting et al ., 1990) . Quantification of PAF bioactivity was performed in a serum was then heat-inactivated (20 min at 56°C). platelet aggregation bioassay as described previously (Ammit and The method of PAF:AH deactivation used in the previously O'Neill, 1991) . reported PAF supplementation trial (O'Neill et al., 1989) involved Phospholipase A 2 and inhibitors acidification of serum by adding 1 M HCl (BDH, Poole, Dorset, UK) dropwise until the pH was 3.0. The pH was measured using a PHM61 Phospholipase A 2 (PLA 2 ; from bee venom, EC 3.1.1.4; Sigma) was laboratory pH meter with a GK2401C combined electrode (Radiometer diluted in 25 mM Tris-buffered saline (pH 8.0; Sigma). Inhibitors of A/S, Copenhagen, Denmark). The acidified serum was incubated for PLA 2 , p-bromophenacyl bromide (Fluka AG, Buchs, Switzerland) 5 min at room temperature before returning the pH to 7.4 by the and mepacrine (quinacrine mustard, dihydrochloride; Sigma) were dropwise addition of 1 M NaOH (BDH). The acid/alkali treatment dissolved in Tyrode's buffer and prepared as 1 mM and 100 µM of serum results in an increase in osmolarity, so the osmolarity of respectively. Dose-response curves for PLA 2 were obtained by adding culture media containing 10% (v/v) acid-treated serum was adjusted 50 µl of PLA 2 /vehicle to the PAF:AH assay. Results were expressed to 280 mosmol/kg by the addition of 'embryo culture grade' water.
as pmol acetate released/min. PLA 2 catalyses the same reaction as Osmolarity was measured by osmometer (Knauer Semi-Micro Osmo-PAF:AH. Concentrations of PLA 2 were chosen that had equivalent meter; Knauer, Oberursel, Germany).
activity to that in the serum pool before and after acid treatment. The effect of PLA 2 inhibitors on PLA 2 and pooled sera were examined by PAF:AH assay adding inhibitors (in 430 µl of Tyrode's buffer) to the PAF:AH assay. PAF:AH was assayed by a slight modification of the method described SDS-PAGE serum profiles by Korth and Middeke (1991 clarify samples. The reducing SDS sample buffer was 62.5 mM Trisreleased being directly proportional to the PAF:AH specific activity.
HCl, pH 6.8 (Sigma); 2% (w/v) SDS (Bio-Rad); 10% (v/v) glycerol The assay was performed at a range of protein concentrations to (BDH); 0.001% (w/v) bromophenol blue (Bio-Rad); 5% (v/v) 2-allow specific activity to be measured. The protein concentration in mercaptoethanol (ICN Biomedicals). Samples (~2-3 mg) were applied serum samples was determined prior to PAF:AH assay using a to PhastGel gradient 10-15% (molecular weight range: 10-250 kDa) modification of the Bio-Rad protein assay (Bio-Rad, Richmond, CA, and detected with combined Coomassie Blue/silver stain (Pharmacia). USA). Bovine serum albumin (BSA) standards (CSL, Melbourne, Interpretation of serum profiles and molecular weight estimations Victoria, Australia) were prepared in Tyrode's buffer (137 mM NaCl, were performed by scanning PhastGels with the PhastImage Gel 2.68 mM KCl, 11.9 mM NaHCO 3 , 1.0 mM MgCl 2 ·6H 2 O, 0.41 mM Analyzer (Pharmacia) to measure the optical density at 603 nm, then Na 2 HPO 4 ·2H 2 O, 0.5 mM glucose, 5.0 mM HEPES, free acid; Sigma comparing the distance of the protein peaks from the cathode with a Chemicals, St Louis, MO, USA). Aliquots (50 µl) were added to molecular weight standard calibration graph, using the PhastImage 5 ml polypropylene tubes and mixed with 2.5 ml of diluted dye Analysis Programme (Version 1.0; Pharmacia). reagent (1 volume Coomassie Brilliant Blue G-250: 4 volumes double-distilled water). After incubation at room temperature for IVF 20 min, the absorbance at 595 nm was measured manually using a spectrophotometer (Varian DMS80; Varian Techtron, Mulgrave, Human oocytes were collected by a transvaginal ultrasound-guided approach following ovarian stimulation. On collection, ova were Victoria, Australia). Before acid treatment, assays were performed at concentrations of 500, 1000, 2500 and 5000 µg protein/ml. After washed extensively and placed individually into 5 ml tissue culture tubes containing 1 ml of human tubal fluid medium (HTFM) with acid treatment, the sera were assayed at 2500, 5000, 10 000 and 25 000 µg protein/ml. 10% (v/v) acid-treated serum. Insemination was performed 5 h later with 80-120ϫ10 3 motile spermatozoa. After incubation at 37°C for The PAF:AH assay reaction mixture contained 430 µl of Tyrode's buffer with 50 µl of test serum or vehicle. After 5 min preincubation 18 h, in 5% CO 2 in air, the fertilization status of the oocytes was checked and the resulting embryos transferred to fresh medium for at 37°C (in a shaking water bath at 100 rpm), the reaction was started by adding 10 µl of 5 µM [ 3 H]acetyl-PAF (10 Ci/mmol; NEN 24 h. During this incubation period, embryos were cultured in the presence of PAF. After 24 h, most embryos had reached the 4-cell Du Pont, Boston, MA, USA) and 10 µl of 245 µM C16:0 PAF (Novabiochem, Laufelfingen, Switzerland). The reaction was stopped stage. A maximum of two embryos were transferred to the uterus and the remaining embryos were cryopreserved. after 15 min by the addition of 100 ml of 170 mg BSA/ml and the tubes were placed on ice for 10 min. Trichloroacetic acid (to a final If menstruation had not occurred 17 days after embryo transfer, urine samples were collected for detection of β-human chorionic concentration of 9 mg/ml) was added to each tube for a further 30 min on ice. The precipitate was removed by centrifugation at gonadotrophin by the Tandem Icon II HCG ImmunoConcentration Assay (Hybritech Incorporated, San Diego, CA, USA). 1500 g for 10 min at 4°C. Aliquots (100 µl) of supernatant were Figure 1 . The amount (%) of platelet-activating factor (PAF) remaining after 24 h incubation of HTFM ϩ 10% (v/v) serum supplemented with 0.8 µg of PAF/ml. Serum was prepared from the women undergoing in-vitro fertilization and was acid-treated (pH 3.0) for 5 min at room temperature.
PAF supplementation of IVF culture medium PAF (L-α-phosphatidylcholine, β-acetyl-γ-O-alkyl; Sigma) was aseptically prepared as 1 mg PAF/ml in chloroform (BDH). A 80 mg PAF/ml stock solution was prepared by placing an aliquot into a siliconized glass tube (Vacutainer; Becton-Dickinson), evaporating the solvent with N 2 and suspending in HTFM with 3 mg human serum albumin/ml. Sterile aliquots (100 ml) of this stock solution were stored at -20°C. A final concentration of 800 ng PAF/ml was prepared by adding 10 µl of the 80 µg PAF/ml stock solution to occurred (Figure 1 ). Of the 18 serum samples examined, five For all analyses, effects were considered to be statistically significant had 90-100% PAF remaining after 24 h (showing that the acid if the probability of the effect being due to chance alone was Ͻ5% (P Ͻ 0.05). treatment was effective), eight had 10-90% of the PAF remaining after 24 h, and five samples only had 0-10%.
Results
PAF:AH specific activity in sera before and after acid treatment Deactivation of PAF:AH in IVF culture medium Sera from 18 females undergoing IVF treatment were used in
The PAF:AH specific activity was measured in the 18 serum samples before and after acid treatment. In untreated samples, a preliminary investigation of the effectiveness of PAF:AH deactivation by acid treatment (pH 3.0) at room temperature the average (mean Ϯ SEM) PAF:AH specific activity was 381.2 Ϯ 32.4 pmol acetate released/min/mg protein (Figure for 5 min. Parallel tubes were prepared containing 10% (v/v) serum which had been either acid-treated or left untreated. 2A). Following acid treatment for 5 min at room temperature, the average PAF:AH specific activity was 12.1 Ϯ 5.6 pmol Each tube was supplemented with 800 ng PAF/ml. To simulate IVF culture conditions, these tubes were incubated for 24 h acetate released/min/mg protein. Some sera were resistant to acid treatment, with several samples still displaying marked (at 37°C in 5% CO 2 in air) and then extracted and partially purified by thin-layer chromatography, and bioassayed for PAF.
PAF:AH activity. There was, however, no correlation between the PAF:AH specific activity (r ϭ 0.023) and the protein In media with serum that was not acid-treated, the amount of PAF remaining was 0.016 Ϯ 0.016% (mean Ϯ SEM) of that concentration (r ϭ 0.003) present in serum before acid treat-ment. There was also no association with age, cause of infertility, or type of ovarian stimulation regimen of the subjects; nor was there correlation between the preovulatory plasma oestradiol peak concentration (7389.2 Ϯ 1407.6 pmol oestradiol/l, mean Ϯ SEM) for these subjects and PAF:AH specific activity, either before (r ϭ 0.042) or after acid treatment (r ϭ 0.026).
Acceptable amounts of PAF:AH for use with PAF supplementation
The regression equation between the amount (%) of PAF remaining after incubation for 24 h and the PAF:AH specific activity in serum after acid treatment was y ϭ 88.2 -17.9x, r ϭ 0.81, P ϭ 0.0004 (after excluding serum samples where no PAF remained) ( Figure 2B , insert). This relationship predicts that the PAF:AH specific activity in serum must be Ͻ0.5 pmol acetate released/min/mg of protein for the PAF to remain largely undegraded. On this basis, it was concluded that acid treatment of sera in 12 of the 18 subjects (67%) was not effective.
Comparison of PAF:AH specific activity in the IVF and a control group
The PAF:AH specific activity (mean Ϯ SEM) in sera from healthy volunteers (n ϭ 20) before and after acid treatment was 390.4 Ϯ 23.7 and 2.7 Ϯ 0.7 pmol acetate released/min/ mg protein respectively. There was no significant difference between the serum PAF:AH specific activity after acid treatment for the control group compared to that collected from IVF subjects (P ϭ 0.11). A similar proportion of sera from the control group was not effectively acid-treated [13/20 (65%) had PAF:AH specific activities Ͼ0.5 pmol acetate released/ technique, and a pool of this serum was prepared.
Data shown are representative results.
Phospholipase A 2 and inhibitors
To exclude the possibility that the persistent PAF:AH-like 37°C, and at this temperature PAF:AH inactivation was complete by 20 min ( Figure 5) . A new acid-treatment protocol of activity was due to long-acyl-chain PLA 2 activity rather than residual PAF:AH, pharmacological inhibitors of PLA 2 20 min at 37°C may be more effective than the earlier protocol of 5 min at room temperature. (p-bromophenacyl bromide and mepacrine) were used to inhibit the activity of PLA 2 . Dose-response curves for PLA 2 were Effectiveness of new acid-treatment protocol established, and a range of concentrations was chosen to give equivalent activity to the serum pool before (1-50 IU/ml) and
The effectiveness of the new acid-treatment protocol was examined in a screen of 53 couples undergoing IVF. Serum after acid treatment (0.1-1.0 IU/ml). Mepacrine and p-bromophenacyl bromide caused significant inhibition of was prepared and split into two fractions and then acid-treated by the two protocols. After 5 min acid treatment at room PLA 2 activity, but had no effect on the enzyme activity in sera before ( Figure 3A and B) or after acid treatment ( Figure 4A temperature, 32 out of 53 sera (60%) had PAF:AH specific activities Ͼ0.5 pmol acetate released/min/mg protein. By and B), indicating that the enzyme in the acid-treated serum which caused some degradation of PAF was not PLA 2 . It was comparison, after acid treatment for 20 min at 37°C, all sera had PAF:AH specific activities Ͻ0.5 pmol acetate released/ therefore assumed that this residual activity was PAF:AH, which was less susceptible to acid deactivation. min/mg protein, showing this protocol to be an effective treatment for the removal of PAF:AH from serum. Development of a new acid treatment protocol SDS-PAGE serum profiles The serum pool was acidified to pH 3.0 with 1 M HCl and maintained for a period of 5, 10, 20, 40 and 80 min at either Figure 6 is a schematic representation of PhastImage analysis of serum from one IVF subject. There were only minor changes room temperature or 37°C, prior to neutralization with 1 M NaOH. Acid treatment was more effective when performed at in the protein profile of the serum following acid treatment Figure 4 . Amount of acetate released (pmol/min) by (A) phospholipase A 2 (PLA 2 ; s) and (B) pooled sera after acid sodium dodecyl sulphate-polyacrylamide gel electrophoresis was performed using a gradient 10-15 PhastGel and a combined treatment for 5 min at room temperature (d), and the effect of the PLA 2 inhibitors p-bromophenacyl bromide (1 mM; u) and Coomassie/silver stain. Interpretation of serum profiles and molecular weight estimations were performed by scanning mepacrine (100 µM; j). Data shown are representative results.
PhastGels with the PhastImage Gel Analyzer to measure the optical density (O.D.) at 603 nm (y-axis), then comparing the distance of the protein peaks from the cathode (x-axis) to a molecular weight standard calibration graph.
at~190 kDa and a marked reduction in the intensity of a band at~170 kDa, while there was the appearance of a band at 105 kDa, possibly due to the formation of subunits after breakdown of the larger acid-labile proteins.
PAF supplementation trial with new acid-treatment protocol
A trial was performed to assess the effect of the new acidtreatment protocol on IVF outcome, following PAF supplementation of IVF culture medium. Women undergoing IVF were alternately allocated to one of two groups (5 min at room temperature versus 20 min at 37°C). A total of 164 IVF treatment cycles were examined in the trial. The oocyte (Table I) . Also, approximately equal activity (pmol acetate released/min/mg protein) of pooled sera.
numbers of embryos were transferred or cryopreserved. The pregnancy rates were not significantly different (13/89 ϭ 14.6% versus 15/75 ϭ 20.0%) for the two treatments, although for 5 min at room temperature. Increasing the acid treatment to 20 min at 37°C did not induce further changes in the profile.
there was a trend towards a higher pregnancy rate with the new acid-treatment protocol. The results show that this new Specifically, acid treatment induced a loss of a protein band each contains PAF:AH. To achieve effective concentrations of PAF added remained bioactive. Thus, the addition of PAF under these circumstances would result in a wide range of effective bioactive PAF concentrations being available to the embryo. It was confirmed that the enzyme activity remaining procedure for acid treatment of serum in combination with after treatment was not due to long-acyl chain PLA 2 , nor was PAF supplementation does not have detrimental effects on it related either to the initial PAF:AH activity of the serum, embryos and their pregnancy outcome and is therefore suitable or to any obvious treatment parameters of the subject. It was for use in IVF. The PAF concentration in media after embryo shown that extension of the treatment time at pH 3.0 enhanced culture was not measured in this study.
the degradation of PAF:AH activity and this was further facilitated by undertaking the acid treatment at 37°C. A Discussion standard protocol of acid treatment for 20 min at 37°C was chosen. This treatment caused all sera tested to have PAF:AH PAF is released by embryos soon after fertilization and throughout the preimplantation phase. While it may impose deactivated to a satisfactory level. The role of complex protein supplements in promoting several effects on maternal physiology during early pregnancy (see Stein and O'Neill, 1994 and references therein), an embryo development (if any) is unknown. Recently the use of defined media with simple protein supplementation, such as important function may be its actions as an autocrine embryotrophic factor. While some studies have failed to detect albumin, has gained some favour. If such protein supplements are homogeneous, they are unlikely to contain PAF:AH activity the release of PAF from embryos (human: Amiel et al., 1989; mouse: Smal et al., 1990) , this was likely to be due to the use and may be compatible with PAF supplementation without the need for acid treatment. The possibility remains that acid of unconventional extraction procedures for PAF assay (Ammit and O'Neill, 1997) . PAF stimulates embryo metabolism (Ryan treatment may cause serum to be an unsuitable media supplement. One consequence is the increase in osmotic strength et al., 1990a), cell-cycle progression (Roberts et al., 1993) and viability (O'Neill et al., 1989; Ryan et al., 1990b) . A common caused by the addition of HCl and NaOH. This was solved by dilution of serum with water and measurement of its osmotic observation has been that the amount of PAF released by embryos is highly variable. A recent study (O'Neill, 1997) strength prior to its use in media. The analysis of protein size with SDS-PAGE before and after acid treatment showed that showed that mouse embryos produced by IVF produced seven times less PAF in vitro than did corresponding embryos at this gross level there were only relatively modest changes in the serum protein profile. In a trial to examine the effect of produced by fertilization in the reproductive tract. Furthermore, the mouse embryos produced by IVF had significantly worse PAF supplementation of culture media on treatment outcome, it was found that extending the acid treatment had no adverse development rates to the blastocyst stage. Supplementation of culture media with PAF resulted in improved development effects on embryo development in vitro or on pregnancy following transfer. There was a non-significant trend for a rates of these embryos. A trial of supplementation of human IVF culture media with PAF also resulted in a significant higher pregnancy rate after use of the harsher acid-treatment protocol. The trial size was, however, too small to draw improvement in embryo viability as assessed by implantation rates (O'Neill et al., 1989) and live-born babies (O'Neill conclusions from this outcome. It is conceivable that acid treatment may have other adverse effects on serum that are et al., 1992) .
It is noteworthy that embryo-derived PAF is detected in IVF not detected by PAGE. A further control of acid-treated serum which was not supplemented with PAF compared to nonculture media, despite the presence of serum which would contain PAF:AH (O'Neill et al., 1987) . Recent studies (Ammit treated serum may help address this. An alternative strategy would be to use serum-free media supplemented with albumin. and O'Neill, 1997) indicate that PAF released from embryos occurs in association with a carrier which protects the PAF PAF supplementation of media with albumin as the only macromolecular supplement was found to increase the viability from the actions of PAF:AH. Exogenous PAF added to culture media does not appear to be able to access this carrier and is and pregnancy rates of mouse embryos following embryo transfer (Ryan et al., 1990b) . susceptible to rapid hydrolysis. Thus, the supplementation of IVF culture media with PAF can be problematic if complex
The results of this study show that an optimized method of acid treatment of serum for the degradation of PAF:AH has protein sources such as serum or follicular fluid are used, since
